Trial Profile
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin or EyleaCompared to Avastin or Eylea Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors IVERIC bio
- 21 Jan 2022 This trial has been completed in Finland (Date of the global end of the trial : 15-Sep-2017), according to European Clinical Trials Database record.
- 11 Jan 2022 This trial has been completed in Norway (end date: 2017-09-15), according to European Clinical Trials Database.
- 18 Dec 2021 This trial was completed in Italy (end date: 2017-09-15), according to European Clinical Trials Database.